u/sofia_wikstrom

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

early fullness on day two and gone by day four is the standard shape

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

Mine settled at week 82 and has not come back since, across two more steps.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

nausea that arrives on day two and fades by day four is the standard shape

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

Reflux was the one that got me. Stopped eating in the three hours before bed and it went from nightly to almost never.

2.4 is a ceiling, not a target

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

That figure is the 68-week trial mean, not a weekly rate. Dividing it by the weeks gives you a number that does not mean anything.

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

intention to treat versus completers changes the number substantially

This is the distinction that would end about half the arguments on this board.

Absolute or relative risk reduction?

Which trial, and which arm?

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the nausea usually fades at a stable dose.

Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Are you tracking heart rate at all?

Kept a log from week one and the single most useful column turned out to be waist, not weight.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

Same. A press release is a claim about a result; the publication is the result.

Severe, or unpleasant? They are genuinely different questions and the answers diverge.

I would not treat a two-kilo range as drift requiring action. That is ordinary weight variation.

First month I lost almost nothing and nearly quit. Month two and three were where it all happened.

FLOW was kidney outcomes and it is the one nobody quotes

Disagree. Severe abdominal pain is not on the list of things to wait out, and this board should not be treating it as one.

A confidence interval is the range of effects compatible with the data.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

Most of the common complaints trace back to slowed gastric emptying — early fullness, reflux, nausea after a large or fatty meal. That is also why meal size and speed change the experience more than anything else.

holding a dose an extra month is a legitimate answer to bad tolerance

the phase 2 numbers were striking and they were also 48 weeks in a small population

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.